E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Aims: The purpose of this study to determine whether the experimental drug ipilimumab stops or delays high-risk melanoma from returning when compared to standard therapy. For high risk melanoma, the current standard treatment is to take high-dose interferon for a year, which causes a number of side effects, or take no treatment. Ipilimumab has been approved by the FDA for use in advanced melanoma. However for high risk melanoma, ipilimumab is still investigational (not FDA approved). Based on prior trials in advanced melanoma, researchers hope that ipilimumab the will be of greater benefit and cause less side effects than interferon in resected high risk melanoma patients.
Diagnosis: Resected High-Risk Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH12-072
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes